| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Andrew Troy Hodge, Suporn Sukpraprut-Braaten, Matthew Narlesky, Robert C Strayha. The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review. Journal of psychoactive drugs. 2022-02-28. PMID:35225726. |
oral psilocybin is showing itself to be clinically efficacious by producing statistically significant reductions in depression and anxiety symptoms over time versus control in multiple clinical trials. |
2022-02-28 |
2023-08-13 |
Not clear |
| Robert B Kargbo, Alexander M Sherwood, Poncho Meisenheimer, Kelsey Lenoch, Solomon Abeb. Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD). ACS omega. vol 7. issue 6. 2022-02-21. PMID:35187358. |
psilocybin, a serotonergic agonist, was granted a "breakthrough therapy" status by the food and drug administration for clinical trials involving major depressive disorder and treatment-resistant depression. |
2022-02-21 |
2023-08-13 |
Not clear |
| Jurriaan F M Strou. [Psilocybin compared with escitalopram for depression]. Nederlands tijdschrift voor geneeskunde. vol 166. 2022-02-09. PMID:35138714. |
[psilocybin compared with escitalopram for depression]. |
2022-02-09 |
2023-08-13 |
Not clear |
| Jurriaan F M Strou. [Psilocybin compared with escitalopram for depression]. Nederlands tijdschrift voor geneeskunde. vol 166. 2022-02-09. PMID:35138714. |
performed a study in which they compared psilocybin in combination with psychotherapy to escitalopram in combination with psychotherapy for depression. |
2022-02-09 |
2023-08-13 |
Not clear |
| Henry J Whitfiel. A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development. Frontiers in psychiatry. vol 12. 2021-12-24. PMID:34950063. |
psychedelic-assisted therapy research for depression and ptsd has been fast tracked in the united states with the food and drugs administration (fda) granting breakthrough designations for mdma (post-traumatic stress disorder) and psilocybin (major depressive disorder). |
2021-12-24 |
2023-08-13 |
Not clear |
| Craig Pearson, Joshua Siegel, Jessica A Gol. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. Journal of the neurological sciences. vol 434. 2021-12-23. PMID:34942586. |
this review provides a comprehensive look at the potential use of psilocybin in the treatment of depression and trd. |
2021-12-23 |
2023-08-13 |
Not clear |
| Craig Pearson, Joshua Siegel, Jessica A Gol. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. Journal of the neurological sciences. vol 434. 2021-12-23. PMID:34942586. |
it includes an overview of the history, pharmacology, and proposed mechanism of psilocybin, and describes several published studies in the last decade which have provided evidence of the efficacy and safety of psilocybin-assisted psychotherapy for individuals with depression. |
2021-12-23 |
2023-08-13 |
Not clear |
| Gabrielle Agin-Liebes, Alan K Davi. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. Current topics in behavioral neurosciences. 2021-11-23. PMID:34811715. |
psilocybin for the treatment of depression: a promising new pharmacotherapy approach. |
2021-11-23 |
2023-08-13 |
human |
| Gabrielle Agin-Liebes, Alan K Davi. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. Current topics in behavioral neurosciences. 2021-11-23. PMID:34811715. |
several lines of evidence from early-phase experimental trials suggest that serotonergic psychedelics, particularly psilocybin, with therapeutic support show great promise in the treatment of depression with large effect sizes. |
2021-11-23 |
2023-08-13 |
human |
| Gabrielle Agin-Liebes, Alan K Davi. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. Current topics in behavioral neurosciences. 2021-11-23. PMID:34811715. |
this chapter reviews the methods and findings from three small human laboratory clinical trials examining the effects of psilocybin therapy for patients with major depressive disorder and treatment-resistant depression. |
2021-11-23 |
2023-08-13 |
human |
| Anna M Becker, Friederike Holze, Tanja Grandinetti, Aaron Klaiber, Vanja E Toedtli, Karolina E Kolaczynska, Urs Duthaler, Nimmy Varghese, Anne Eckert, Edna Grünblatt, Matthias E Liecht. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clinical pharmacology and therapeutics. 2021-11-22. PMID:34743319. |
the psychedelic psilocybin is being investigated for the treatment of depression and anxiety. |
2021-11-22 |
2023-08-13 |
human |
| Susan Ling, Felicia Ceban, Leanna M W Lui, Yena Lee, Kayla M Teopiz, Nelson B Rodrigues, Orly Lipsitz, Hartej Gill, Mehala Subramaniapillai, Rodrigo B Mansur, Kangguang Lin, Roger Ho, Joshua D Rosenblat, David Castle, Roger S McIntyr. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS drugs. 2021-11-18. PMID:34791625. |
molecular mechanisms of psilocybin and implications for the treatment of depression. |
2021-11-18 |
2023-08-13 |
Not clear |
| Nan-Xi Li, Yi-Ru Hu, Wang-Ni Chen, Bin Zhan. Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. Journal of affective disorders. vol 296. 2021-11-15. PMID:34587546. |
dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. |
2021-11-15 |
2023-08-13 |
Not clear |
| Nan-Xi Li, Yi-Ru Hu, Wang-Ni Chen, Bin Zhan. Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. Journal of affective disorders. vol 296. 2021-11-15. PMID:34587546. |
in the current study, we aim to explore the dose effects of psilocybin on primary (major depression patients) and secondary depression (depressed cancer patients). |
2021-11-15 |
2023-08-13 |
Not clear |
| Flora Graha. Daily briefing: Largest trial shows psilocybin is effective to treat depression. Nature. 2021-11-12. PMID:34764467. |
daily briefing: largest trial shows psilocybin is effective to treat depression. |
2021-11-12 |
2023-08-13 |
Not clear |
| Lea J Mertens, Katrin H Prelle. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders. Pharmacopsychiatry. vol 54. issue 4. 2021-10-28. PMID:33472250. |
modern clinical research is currently gaining momentum and provides new evidence for the safety and efficacy of classical psychedelics (primarily psilocybin, but also lsd and ayahuasca) in the treatment of different psychiatric conditions, including substance use and mood disorders.in this review article, we outline common pathological mechanisms of substance use disorders (sud) and unipolar depression. |
2021-10-28 |
2023-08-13 |
human |
| Sandeep M Nayak, Natalie Gukasyan, Frederick S Barrett, Earth Erowid, Fire Erowid, Roland R Griffith. Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. Pharmacopsychiatry. vol 54. issue 5. 2021-10-28. PMID:34348413. |
this is important to know, as individuals with bipolar depression may attempt to treat themselves with psychedelics while on a mood stabilizer, particularly given enthusiastic media reports of the efficacy of psilocybin for depression. |
2021-10-28 |
2023-08-13 |
Not clear |
| Teresa Kay Jones, Steven Lippman. Psilocybin Can Diminish Depression. The primary care companion for CNS disorders. vol 22. issue 5. 2021-10-15. PMID:32898345. |
psilocybin can diminish depression. |
2021-10-15 |
2023-08-13 |
Not clear |
| Igor Magaraggia, Zilla Kuiperes, Rudy Schreibe. Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach. Neurobiology of learning and memory. vol 183. 2021-09-22. PMID:34048913. |
at the psychobiological level, we hypothesize that the negativity bias in mdd is due to impaired pattern separation and that psychedelics such as psilocybin help in depression because they enhance pattern separation and hence reduce negativity bias. |
2021-09-22 |
2023-08-13 |
Not clear |
| Joshua F Wiley, Bei Be. Psilocybin for Depression. The New England journal of medicine. vol 385. issue 9. 2021-09-06. PMID:34437794. |
psilocybin for depression. |
2021-09-06 |
2023-08-13 |
Not clear |